Drug intelligence / Profile preview

GT-653

Development stage: Unknown
Lead developer: 华东师范大学
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

GT-653: sourced facts only. name: "Among them, GT-653 showed optimal KDM5B degradation efficiency in a ubiquitin proteasome-dependent manner." [PMID:38749268]; target: "Among them, GT-653 showed optimal KDM5B degradation efficiency in a ubiquitin proteasome-dependent manner." [PMID:38749268]; developer: "Shanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, 200241, China." [PMID:38749268]; modality: "Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer." [PMID:38749268]

Targets

KDM5B (Lysine-specific demethylase 5B)

Beyond the preview

Go deeper on GT-653.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT-653.